SM08502 + FOLFIRI + panitumumab

**SM08502 + FOLFIRI + panitumumab** is an investigational combination regimen under clinical evaluation primarily for advanced or metastatic colorectal cancer. \n- **SM08502** is a novel, investigational small molecule inhibitor targeting aberrant Wnt signaling, a pathway commonly implicated in colorectal and other cancers. \n- **FOLFIRI** is a standard chemotherapy regimen, comprising folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. These agents disrupt DNA synthesis and cell division, primarily through inhibition of thymidylate synthase (by 5-FU), DNA damage incorporation (5-FU), and inhibition of topoisomerase I (irinotecan)[1][2][3][4][5]. \n- **Panitumumab** is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking the signaling pathways that promote cancer cell proliferation and survival. \nThe regimen combines cytotoxic, targeted therapy, and pathway inhibition to enhance antitumor activity, particularly in patients with metastatic colorectal cancer who may have failed prior therapies. \nClinical trials are ongoing.

Other names

SM08502 + FOLFIRI + panitumumab